Antiviral Research 2016-01-01

The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus.

Laura K McMullan, Mike Flint, Julie Dyall, César Albariño, Gene G Olinger, Scott Foster, Phiroze Sethna, Lisa E Hensley, Stuart T Nichol, E Randall Lanier, Christina F Spiropoulou

Index: Antiviral Res. 125 , 71-8, (2016)

Full Text: HTML

Abstract

Brincidofovir (BCV) is the 3-hexadecyloxy-1-propanol (HDP) lipid conjugate of the acyclic nucleoside phosphonate cidofovir (CDV). BCV has established broad-spectrum activity against double-stranded DNA (dsDNA) viruses; however, its activity against RNA viruses has been less thoroughly evaluated. Here, we report that BCV inhibited infection of Ebola virus in multiple human cell lines. Unlike the mechanism of action for BCV against cytomegalovirus and other dsDNA viruses, phosphorylation of CDV to the diphosphate form appeared unnecessary. Instead, antiviral activity required the lipid moiety and in vitro activity against EBOV was observed for several HDP-nucleotide conjugates.Copyright © 2015. Published by Elsevier B.V.